Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.46 |
| ▸ | INSR | P06213 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NPM1 | P06748 | 6/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520634 | 0.86 | JAK2 (0.50) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL521498 | 0.82 | JAK2 (0.55) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL2502680 | 0.81 | ALK (0.54) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL2502679 | 0.80 | ALK (0.41) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL17577024 | 0.78 | JAK2 (0.60) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL2509986 | 0.77 | JAK2 (0.47) | JAK2PTK2 | |
| SCHEMBL519921 | 0.77 | JAK2 (0.59) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL520547 | 0.77 | JAK2 (0.59) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL521729 | 0.76 | JAK2 (0.52) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL522266 | 0.75 | JAK2 (0.55) | JAK2ALKINSRCYP3A4NPM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |